Literature DB >> 15670246

Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.

C J Achenbach1, M Till, F J Palella, M D Knoll, S M Terp, A U Kalnins, R L Murphy.   

Abstract

OBJECTIVES: Evaluation of extended treatment interruption (TI) in chronic HIV infection among patients successfully treated with antiretroviral therapy.
METHODS: An observational analysis of 25 patients in a prospectively followed cohort with chronic HIV infection, viral loads <500 HIV-1 RNA copies/mL for at least 6 months, and an interruption in therapy of >/=28 days duration was carried out. Follow up was divided into 3-month time periods for analysis. The effects of time period, stratification group and stratification group by time period interactions on CD4 counts were tested using a mixed model. Univariate comparisons among patient characteristics and responses were performed using Fisher's exact test or the Wilcoxon rank sum test.
RESULTS: At initiation of TI, the median CD4 count was 799 cells/microL. TI duration was a median of 7.1 months. HIV RNA rebounded to a median maximum level of 75 000 copies/mL. Maximum viral rebound was significantly greater in patients who were male, had lipodystrophy and had zenith HIV RNA prior to TI of >/=50 000 copies/mL. Lower CD4 cell counts were observed during TI in patients with lipodystrophy, zenith HIV RNA >/=50 000 copies/mL, history of AIDS, HIV infection >/=5 years and presuppression CD4 count </=350 cells/muL. Patients who reinitiated therapy had shorter TI duration, presuppression CD4 count </=350 cells/microL, previous AIDS diagnosis and lipodystrophy. No patients developed adverse or AIDS-defining events during TI.
CONCLUSIONS: Long-term TI resulted in greater immune deterioration in patients with high viral set points or low CD4 cell counts prior to initiation of suppressive antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15670246     DOI: 10.1111/j.1468-1293.2005.00257.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  3 in total

1.  Association of early HIV viremia with mortality after HIV-associated lymphoma.

Authors:  Satish Gopal; Monita R Patel; Elizabeth L Yanik; Stephen R Cole; Chad J Achenbach; Sonia Napravnik; Greer A Burkholder; Erin G Reid; Benigno Rodriguez; Steven G Deeks; Kenneth H Mayer; Richard D Moore; Mari M Kitahata; Kristy L Richards; Joseph J Eron
Journal:  AIDS       Date:  2013-09-24       Impact factor: 4.177

2.  Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects.

Authors:  Gemma Hancock; Sara Morón-López; Jakub Kopycinski; Maria C Puertas; Eleni Giannoulatou; Annie Rose; Maria Salgado; Emma-Jo Hayton; Alison Crook; Catharine Morgan; Brian Angus; Fabian Chen; Hongbing Yang; Javier Martinez-Picado; Tomas Hanke; Lucy Dorrell
Journal:  J Int AIDS Soc       Date:  2017-05-19       Impact factor: 5.396

3.  Immunological predictors of CD4+ T cell decline in antiretroviral treatment interruptions.

Authors:  Elena Seoane; Salvador Resino; Santiago Moreno; Juan Carlos Lopez Bernaldo de Quiros; Ana Moreno; Rafael Rubio; Juan Gonzalez-García; José Ramón Arribas; Federico Pulido; Ma Angeles Muñoz-Fernández
Journal:  BMC Infect Dis       Date:  2008-02-26       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.